Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/897
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Dextrose (Injection, Solution)
|
| dailymed-instance:dosage |
As directed by a
physician. Dosage is
dependent upon the age,
weight and clinical
condition of the
patient as well as
laboratory
determinations. Parenteral drug
products should be
inspected visually for
particulate matter and
discoloration prior to administration whenever
solution and container
permit. All injections in
VIAFLEX plastic
containers are intended
for intravenous administration using
sterile equipment. Additives may be
incompatible. Complete
information is not
available. Those additives known
to be incompatible
should not be used.
Consult with
pharmacist, if
available. If, in the
informed judgment of
the physician, it is
deemed advisable to introduce additives,
use aseptic technique.
Mix thoroughly when
additives have been
introduced. Do not
store solutions
containing
additives.
|
| dailymed-instance:descripti... |
Dextrose Injection,
USP is a sterile,
nonpyrogenic solution
for fluid replenishment
and caloric supply in
single dose containers
for intravenous
administration. It
contains no
antimicrobial agents.
Composition, osmolarity, pH, and
caloric content are
shown in Table 1. The VIAFLEX plastic
container is fabricated
from a specially
formulated polyvinyl
chloride (PL 146
Plastic). The amount of
water that can permeate
from inside the
container into the
overwrap is insufficient to affect the solution
significantly.
Solutions in contact
with the plastic
container can leach out
certain of its chemical
components in very
small amounts within
the expiration period,
e.g., di-2-ethylhexyl
phthalate (DEHP), up to
5 parts per million.
However, the safety of
the plastic has been
confirmed in tests in
animals according to
USP biological test for
plastic containers as
well as by tissue
culture toxicity
studies.
|
| dailymed-instance:clinicalP... |
Dextrose Injection,
USP has value as a
source of water and
calories. It is capable
of inducing diuresis
depending on the clinical condition of
the patient.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
Solutions containing
dextrose may be
contraindicated in
patients with known
allergy to corn or corn
products.
|
| dailymed-instance:supply |
Dextrose Injection,
USP in VIAFLEX plastic container is available
as follows: Exposure of
pharmaceutical products
to heat should be
minimized. Avoid
excessive heat. It is
recommended the product
be stored at room
temperature
(25��C/77��F); brief
exposure up to
40��C/104��F does not
adversely affect the
product.<br/>Directions
For Use Of
VIAFLEX
Plastic
Container: Warning:
Do
not
use
plastic
containers
in
series
connections.
Such
use
could
result
in
air
embolism
due
to
residual
air
being drawn
from
the
primary
container
before administration
of
the
fluid
from
the
secondary
container
is
completed.<br/>To Open: Tear
overwrap
down
side
at
slit
and
remove
solution
container.
Some
opacity
of
the
plastic
due
to
moisture
absorption during
the
sterilization
process
may
be
observed.
This
is
normal
and
does
not
affect
the
solution quality
or
safety.
The
opacity
will
diminish
gradually.
Check
for
minute
leaks
by
squeezing
inner
bag
firmly.
If
leaks
are found,
discard
solution
as
sterility
may
be
impaired.
If
supplemental
medication
is
desired,
follow���To
Add
Medication���directions
below.<br/>Preparation
for
Administration: 1.
Suspend
container
from
eyelet
support. 2. Remove
plastic
protector
from
outlet
port
at
bottom
of
container. 3.
Attach
administration
set.
Refer
to
complete
directions
accompanying
set.<br/>To Add
Medication: Warning:
Additives
may
be
incompatible.<br/>To add
medication
before
solution administration: 1
Prepare
medication
site. 2
Using
syringe
with
19
to
22
gauge
needle,
puncture
resealable
medication
port
and
inject. 3
Mix
solution
and medication
thoroughly. For
high
density
medication
such
as
potassium
chloride,
squeeze
ports
while
ports
are
upright
and
mix
thoroughly.<br/>To add
medication
during solution
administration: 1
Close
clamp
on
the
set. 2
Prepare medication
site. 3
Using
syringe
with
19
to
22
gauge
needle,
puncture
resealable
medication port
and
inject. 4
Remove
container
from
IV
pole
and/or
turn
to
an
upright
position. 5
Evacuate
both
ports
by
squeezing them
while
container
is
in
the
upright
position. 6
Mix
solution
and
medication
thoroughly. 7
Return
container
to
in-use
position
and
continue
administration. Baxter
Healthcare
Corporation Deerfield,
IL
60015 USA Printed
in
USA
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:precautio... |
Clinical evaluation
and periodic laboratory
determinations are
necessary to monitor
changes in fluid
balance, electrolyte
concentrations and acid
base balance during
prolonged parenteral
therapy or whenever the
condition of the
patient warrants such
evaluation. Dextrose Injection,
USP should be used with
caution in patients
with overt subclinical
diabetes mellitus.<br/>Pregnancy:<br/>Teratogenic
Effects:<br/>Pediatric
Use: Dextrose
is
safe
and
effective
for
the
stated
indications
in
pediatric
patients
(seeINDICATIONS
AND
USAGE).
As reported
in
the
literature,
the
dosage
selection
and
constant
infusion
rate
of
intravenous
dextrose
must
be
selected
with
caution
in
pediatric
patients,
particularly
neonates
and
low
birth
weight
infants,
because
of the
increased
risk
of
hyperglycemia/hypoglycemia. Frequent
monitoring
of
serum
glucose
concentrations
is
required
when
dextrose
is
prescribedto
pediatric
patients,
particularly
neonates
and
low
birth
weight
infants. Do
not
administer
unless
solution is
clear
and
seal
is
intact.
|
| dailymed-instance:genericMe... |
Dextrose monohydrate
|
| dailymed-instance:fullName |
Dextrose (Injection, Solution)
|
| dailymed-instance:adverseRe... |
Reactions which may
occur because of the
injection or the technique of
administration include
febrile response,
infection at the site
of injection, venous
thrombosis or phlebitis
extending from the site
of injection,
extravasation and
hypervolemia. If an adverse reaction
does occur, discontinue
the infusion, evaluate
the patient, institute
appropriate therapeutic
countermeasures and
save the remainder of
the fluid for
examination if deemed necessary.
|
| dailymed-instance:warning |
Dextrose Injection,
USP should not be
administered
simultaneously with
blood through the same
administration set
because of the
possibility of
pseudoagglutination or
hemolysis. The intravenous
administration of these
solutions can cause fluid and/or solute overloading resulting
in dilution of serum
electrolyte
concentrations,
overhydration,
congested states, or
pulmonary edema. The
risk of dilutive states
is inversely
proportional to the
electrolyte
concentrations of the
injections. The risk of
solute overload causing
congested states with
peripheral and
pulmonary edema is
directly proportional
to the electrolyte
concentrations of the
injections. Excessive
administration of
dextrose injections may
result in significant
hypokalemia. In very low birth
weight infants, excessive or rapid
administration of
dextrose injection may
result in increased
serum osmolality and
possible intracerebral
hemorrhage.
|
| dailymed-instance:indicatio... |
Dextrose Injection,
USP is indicated as a
source of water and
calories.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Dextrose
|